Inborn errors of metabolism:
Indications for SCENESSE:
To increase pain free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.
See full labeling. Use an SFM implantation cannula or other suitable devices. ≥18yrs: Insert 1 implant subcutaneously above the anterior supra-iliac crest every 2 months.
<18yrs: not established.
Should be administered by an experienced health care provider. Pre-existing nevi and ephelides. Monitor skin pigmentary lesions; perform full body skin exam twice yearly. Advise patients to maintain sun and light protection measures during treatment to prevent phototoxic reactions. Pregnancy. Nursing mothers.
Melanocortin receptor agonist.
Implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, skin irritation; skin pigmentation/darkening.
Half-life: ~15 hours.
Generic Drug Availability:
Implant (in vial)—1